Neuro-oncology C-Cert Learning Objectives and CME

C-cert Activity Description

The Continuous Certification (C-cert) activities provide subspecialty learning and knowledge assessment to ensure that diplomates are staying up to date on the latest science, treatments, and therapeutics relating to their subspecialty. The annual activities include: 1) reading the subspecialty Reading List of journal articles, and 2) taking and passing the 25-question online post-reading quiz to assess knowledge gained from the journal article content. 

Learning Objectives

Upon completion of this UCNS C-cert activity, participants will be able to:
  • Identify the survival benefit from tumor treating fields (TTF) therapy for glioblastoma multiforme (GBM) patients and increase its utilization in their practice
  • Recognize the role of radiotherapy for pediatric ependymoma
  • Recognize the survival benefit from chemoRT for “lower” grade gliomas

Core Competencies

This UCNS C-cert activity covers the following core competency:
  • Medical Knowledge

AMA Credit Designation Statement

The American Academy of Neurology Institute designates this enduring material for a maximum of 11 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Medical Education (CME) Instructions

To claim CME credits, answer question 26 on the quiz to reflect the total time spent completing the required reading and online quiz. This question is not included in the scoring of the quiz. A passing score of 80% of higher is needed to meet C-cert requirements and receive CME credit. CME credit confirmation will be emailed within ten business days of passing the quiz.

ACCME Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Academy of Neurology Institute (AANI) and United Council for Neurologic Subspecialties. The AANI is accredited by the ACCME to provide continuing medical education for physicians.

Disclosures

The UCNS complies with all standards and policies of the ACCME, including identification and resolution of all conflicts of interest prior to the educational activity being delivered to learners. Accordingly, UCNS  planners, authors, and staff comply with the UCNS’s Conflicts of Interest Policy

Neuro-oncology Certification Examination Committee Contributors


Jeffrey C. Allen, MD, FAAN, NYU Langone Medical Center

Disclosures: Receives grant support from Department of Defense for institutional leadership of a grant for the NF Clinical Trials Consortium.

Joy Ellen Burke, MD, University of Rochester
Disclosures: Receives compensation for consulting with Allergan regarding a migraine product.

Howard Colman, MD, Chair, University of Utah Huntsman Cancer Institute
Disclosures: Serves on Advisory Board/Consultant for Best Doctors, Karyopharm Therapeutics, Private Health, Orbus, Bayer, and Forma Therapeutics. Receives research Funding (Site PI/Institutional Contract) from Newlink Genetics, Plexxikon, Kadmon, Orbus, Merck, DNATrix, Abbvie, Beigene, Forma Therapeutics, GCAR, and Array BioPharma. Receives research funding and research-related salary support from National Institutes of Health/National Cancer Institute, Alliance NCORP Research Base, NIH/NINDS, Huntsman Cancer Institute, and Jon M. Huntsman Presidential Endowed Chair.

Kurt A. Jaeckle, MD, FAAN, Atlanta Health System
Disclosures: Holds stock in Entegrion, Inc.

Yasmine Khakoo, MD, Memorial Sloan Kettering Cancer Center
Disclosures: Nothing to disclose.

Minesh P. Mehta, MD, Vice Chair, University of Maryland Medical School
Disclosures: Is a consultant with Karyopharm and serves as member of the Board of directors for Tocagen; Board of Directors: Oncoceutics; Received Oncoceutics 0.1% stock-option investment as a member of the Board of Directors.

Tom Mikkelsen, MD, Ontario Brain Institute
Disclosures: Hosted Society for Neuro-Oncology (SNO) dinner satellite symposium: “Tyrosine Kinase Inhibitors in Glioblastoma: Refining Precision Medicine” on Friday, November 22, 2019 sponsored by Clinical Care Options, LLC.

Douglas E. Ney, MD, University of Colorado School of Medicine
Disclosures: Receives compensation to serve on DNAtrix Therapeutics - Data Safety Monitoring Board. Receives research support from Orbus Therapeutics for role as Principal Investigator of national multi-site clinical trial and from Genentech for role as Principal Investigator of national multi-site clinical trial.

Nina Paleologos, MD, Advocate Good Samaritan Hospital
Disclosures: Nothing to disclose.

Roy E. Strowd, III, MD, MEd, Wake Forest School of Medicine
Disclosures: Has commercial relationships with Monteris Medical, Novocure Inc, and Lecturio. Receives research support from American Society of Clinical Oncology, JAZZ Pharmaceuticals, and Southeastern Brain Tumor Foundation.

Staff Contact

Todd Bulson, Senior Manager Certification
tbulson@ucns.org
(612) 928-6067

Becky Swanson, Operations and Executive Office Manager
bswanson@ucns.org
(612) 928-6050